β-adrenergic receptors in cancer: Therapeutic implications

Oncology Research

Volumn 19, Issue 1, 2010, Pages 45-54

  Pérez Sayáns, Mario ^a   Somoza Martín, José Manuel ^a   Barros Angueira, Francisco ^b   Diz, Pilar Gayoso ^c   Rey, José Manuel Gándara ^a   García Garcí, Abel ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

ADRB2; Apoptosis; Chemotaxis; adrenergic agonist; adrenergic antagonist; adrenergic receptors

Indexed keywords

ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; ANDROGEN; ARA 211; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUTOXAMINE; CATECHOLAMINE; CYANOPINDOLOL I 125; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOPRENALINE; METOPROLOL; NEUROTRANSMITTER; NORADRENALIN; PIRBUTEROL; PROPRANOLOL; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANGIOGENESIS; APOPTOSIS; BINDING SITE; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL STRESS; CHEMOTAXIS; CHRONIC LYMPHATIC LEUKEMIA; DRUG MECHANISM; GLYCOSYLATION; HUMAN; LUNG ADENOCARCINOMA; METASTASIS; NONHUMAN; PALMITOYLATION; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR BLOCKING; REVIEW; TUMOR GROWTH;

EID: 79951482448     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12828372551867     Document Type: Review

References (80)

1. Boyd, N. M.; Reade, P. C. Mechanisms of carcinogenesis with particular reference to the oral mucosa. J. Oral Pathol. 17:193-201; 1988.
2. Rajeevan, M. S.; Vernon, S. D.; Taysavang, N.; Unger, E. R. Validation of array-based gene expression profiles by real-time (kinetic) RT-PCR. J. Mol. Diagn. 3:26-31; 2001.
3. Meinhardt, G.; Wendtner, C. M.; Hallek, M. Molecular pathogenesis of chronic lymphocytic leukemia: Factors and signaling pathways regulating cell growth and survival. J. Mol. Med. 77:282-293; 1999.
4. Sastry, K. S.; Karpova, Y.; Prokopovich, S.; Smith, A. J.; Essau, B.; Gersappe, A.; et al. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J. Biol. Chem. 282:14094-14100; 2007.
5. Entschladen, F.; Lang, K.; Drell, T. L.; Joseph, J.; Zaenker, K. S. Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol. Immunother. 51:467-482; 2002.
6. Lang, K.; Drell, 4th, T. L.; Lindecke, A.; Niggemann, B.; Kaltschmidt, C.; Zaenker, K. S.; et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int. J. Cancer 11:231-238; 2004.
7. Shang, Z. J.; Liu, K.; Liang de, F. Expression of beta2-adrenergic receptor in oral squamous cell carcinoma. J. Oral Pathol. Med. 38:371-376; 2009.
8. Johnson, M. Beta2-adrenoceptors: Mechanisms of action of beta2-agonists. Paediatr. Respir. Rev. 2:57-62; 2001.
9. Strader, C. D.; Candelore, M. R.; Hill, W. S.; Sigal, I. S.; Dixon, R. A. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J. Biol. Chem. 264:13572-13578; 1989.
10. Benovic, J. L.; Pike, L. J.; Cerione, R. A.; Staniszewski, C.; Yoshimasa, T.; Codina, J.; et al. Phosphorylation of the mammalian beta-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. J. Biol. Chem. 260:7094-7101; 1985.
11. Wallukat, G. The beta-adrenergic receptors. Herz 27:683-690; 2002.
12. Lefkowitz, R. J. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J. Biol. Chem. 273:18677-18680; 1998.
13. Audet, M.; Bouvier, M. Insights into signaling from the beta2-adrenergic receptor structure. Nat. Chem. Biol. 4:397-403; 2008.
14. Pitcher, J.; Lohse, M. J.; Codina, J.; Caron, M. G.; Lefkowitz, R. J. Desensitization of the isolated beta 2-adrenergic receptor by beta-adrenergic receptor kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms. Biochemistry 31:3193-3197; 1992.
15. Kobilka, B. K.; Dixon, R. A.: Frielle, T.; Dohlman, H. G.; Bolanowski, M. A. Sigal, I. S.; et al. cDNA for the human beta 2-adrenergic receptor: A protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc. Natl. Acad. Sci. USA 84:46-50; 1987.
16. Silverman, E. K.; Kwiatkowski, D. J.; Sylvia, J. S.; Lazarus, R.; Drazen, J. M. C.; Lange, C.; et al. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. J. Allergy Clin. Immunol. 112:870-876; 2003.
17. Martinez, J. A.; Corbalan, M. S.; Sanchez-Villegas, A.; Forga, L.; Marti, A.; Martinez-Gonzalez, M. A. Obesity risk is associated with carbohydrate intake in women carrying the Gln27Glu beta2-adrenoceptor polymorphism. J. Nutr. 133:2549-2554; 2003.
18. Wang, H.; Hao, B.; Chen, X.; Zhao, N.; Cheng, G.; Jiang, Y.; et al. Beta-2 adrenergic receptor gene (ADRB2) polymorphism and risk for lung adenocarcinoma: A case-control study in a Chinese population. Cancer Lett. 240:297-305; 2006.
19. Murphy, P. M. Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med. 345:833-835; 2001.
20. Moore, M. A. The role of chemoattraction in cancer metastases. Bioessays 23:674-676; 2001.
21. Maestroni, G. J. Dendritic cell migration controlled by alpha 1b-adrenergic receptors. J. Immunol. 165:6743-6747; 2000.
22. Elferink, J. G.; VanUffelen, B. E. The role of cyclic nucleotides in neutrophil migration. Gen. Pharmacol. 27:387-393; 1996.
23. Howard, O. M.; Ben-Baruch, A.; Oppenheim, J. J. Chemokines: Progress toward identifying molecular targets for therapeutic agents. Trends Biotechnol. 14:46-51; 1996.
24. Masur, K.; Niggemann, B.; Zanker, K. S.; Entschladen, F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res. 61:2866-2869; 2001.
25. Chelmicka-Schorr, E.; Arnason, B. G.; Holshouser, S. J. C-6 glioma growth in rats: Suppression with a beta-adrenergic agonist and a phosphodiesterase inhibitor. Ann. Neurol. 8:447-449; 1980.
26. Cho-Chung, Y. S.; Clair, T.; Tagliaferri, P.; Ally, S.; Katsaros, D.; Tortora, G.; et al. Site-selective cyclic AMP anator logs as new biological tools in growth control, differentiation, and proto-oncogene regulation. Cancer Invest. 7: 161-177; 1989.
27. Paul-Eugene, N.; Dugas, B.; Gordon, J.; Kolb, J. P.; Cairns, J. A.; Paubert-Braquet, M.; et al. Beta 2-adrenoceptor stimulation augments the IL-4-induced CD23 expression and release and the expression of differentiation markers (CD14, CD18) by the human monocytic cell line, U 937. Clin. Exp. Allergy 23:317-325; 1993.
28. Kinnard, R. L.; Chelmicka-Schorr, E.; Checinski, M. E.; Jones, K. H.; Arnason, B. G. Sympathetic nervous system and glioma growth. Eur. J. Cancer Clin. Oncol. 22:501-503; 1986.
29. Chelmicka-Schorr, E.; Sportiello, M. G.; Atweh, S. F.; Arnason, B. G. Response of C-6 glioma to isoproterenol and papaverine in vivo depends on beta-adrenergic receptor density. Ann. Neurol. 15:96-99; 1984.
30. D'Amico, C.; Crescimanno, M.; Armata, M. G.; Leonardi, V.; Palazzoadriano, M.; D'Alessandro, N. Beta-adrenergic influences on doxorubicin-sensitive or -resistant P388 leukemia cells. Anticancer Res. 12:2253-2256; 1992.
31. Lange-Carter, C. A.; Droms, K. A.; Vuillequez, J. J.; Malkinson, A. M. Differential responsiveness to agents which stimulate cAMP production in normal versus neoplastic mouse lung epithelial cells. Cancer Lett. 67:139-144; 1992.
32. Kondratenko, T. Y.; Zacharova, I. V.; Kuzina, N. V.; Katukov, V. Y.; Severin, E. S.; Kornilova, Z. C.; et al. Alterations in human lung adrenergic receptors in cancer. Biochem. Mol. Biol. Int. 29:123-130; 1993.
33. Qing, F.; Hayes, M. J.; Rhodes, C. G.; Krausz, T.; Fountain, S. W.; Burke, M. M.; et al. Reduced beta adrenoceptor sensity in vivo in human lung tumours: A preliminary study with positron emission tomography. Thorax 51:727-732; 1996.
34. Gope, R.; Gope, M. L.; Thorson, A.; Christensen, M.; Smyrk, T.; Chun, M.; et al. Genetic changes at the beta-2-adrenergic receptor locus on chromosome 5 in human colorectal carcinomas. Anticancer Res. 11:2047-2050; 1991.
35. Hughes, R. J.; Howard, M. J.; Allen, J. M.; Insel, P. A. Decreased beta 2-adrenergic receptor mRNA expression in receptor-deficient S49 lymphoma cells. Mol. Pharmacol. 40:974-979; 1991.
36. Straub, R. H.; Mayer, M.; Kreutz, M.; Leeb, S.; Scholmerich, J.; Falk, W. Neurotransmitters of the sympathetic nerve terminal are powerful chemoattractants for monocytes. J. Leukoc. Biol. 67:553-558; 2000.
37. Lang, K.; Drell, T. L.; Niggemann, B.; Zanker, K. S.; Entschladen, F. Neurotransmitters regulate the migration and cytotoxicity in natural killer cells. Immunol. Lett. 90:165-172; 2003.
38. Schuller, H. M.; Porter, B.; Riechert, A. Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters. J. Cancer Res. Clin. Oncol. 126:624-630; 2000.
39. Luttrell, L. M.; Lefkowitz, R. J. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell. Sci. 115:455-465; 2002.
40. Luttrell, L. M.; Ferguson, S. S.; Daaka, Y.; Miller, W. E.; Maudsley, S.; Della Rocca, G. J.; et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283:655-661; 1999.
41. Revankar, C. M.; Vines, C. M.; Cimino, D. F.; Prossnitz, E. R. Arrestins block G protein-coupled receptor-mediated apoptosis. J. Biol. Chem. 279:24578-24584; 2004.
42. Green, D. R.; Evan, G. I. A matter of life and death. Cancer Cell 1:19-30; 2002.
43. Schuller, H. M.; Witschi, H. P.; Nylen, E.; Joshi, P. A.; Correa, E.; Becker, K. L. Pathobiology of lung tumors induced in hamsters by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the modulating effect of hyperoxia. Cancer Res. 50:1960-1965; 1990.
44. Schuller, H. M.; Cole, B. Regulation of cell proliferation by beta-adrenergic receptors in a human lung adenocarcinoma cell line. Carcinogenesis 10:1753-1755; 1989.
45. Sheppard, J. R.; Gormus, R.; Moldow, C. F. Catecholamine hormone receptors are reduced on chronic lymphocytic leukaemic lymphocytes. Nature 269:693-695; 1977.
46. Luthy, I. A.; Bruzzone, A.; Pinero, C. P.; Castillo, L. F.; Chiesa, I. J.; Vazquez, S. M.; et al. Adrenoceptors: Non conventional target for breast cancer? Curr. Med. Chem. 16:1850-1862; 2009.
47. Kamp, T.; Liebl, B.; Haen, E.; Emmerich, B.; Hallek, M. Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: Relationship to disease progression. Eur. J. Clin. Invest. 27:121-127; 1997.
48. McGraw, D. W.; Liggett, S. B. Molecular mechanisms of beta2-adrenergic receptor function and regulation. Proc. Am. Thorac. Soc. 2:292-296, 311-312; 2005.
49. Zhang, D.; Ma, Q.; Shen, S.; Hu, H. Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: The study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell. Pancreas 38:94-100; 2009.
50. Kassahun, W. T.; Gunl, B.; Tannapfel, A.; Ungemach, F. R.; Hauss, J.; Abraham, G. Alpha1-and beta2-adrenoceptors in the human liver with mass-forming intrahepatic cholangiocarcinoma: density and coupling to adenylate cyclase and phospholipase C. Naunyn Schmiedebergs Arch. Pharmacol. 372:171-181; 2005.
51. Carie, A. E.; Sebti, S. M. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene 26:3777-3788; 2007.
52. Drell, 4th, T. L.; Joseph, J.; Lang, K.; Niggemann, B.; Zaenker, K. S.; Entschladen, F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res. Treat. 80:63-70; 2003.
53. Palm, D.; Lang, K.; Niggemann, B.; Drell, 4th, T. L.; Masur, K.; Zaenker, K. S.; et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int. J. Cancer 118:2744-2749; 2006.
54. Felten, D. L. Direct innervation of lymphoid organs: Substrate for neurotransmitter signaling of cells of the immune system. Neuropsychobiology 28:110-112; 1993.
55. Khan, M. Z.; Freshney, R. I.; McNicol, A. M.; Murray, A. M. Induction of phenotypic changes in SCLC cell lines in vitro by hexamethylene bisacetamide, sodium butyrate, and cyclic AMP. Ann. Oncol. 4:499-507; 1993.
56. Rozengurt, E. Early signals in the mitogenic response. Science 234:161-166; 1986.
57. Beebe, S. J.; Koch, S. R.; Chu, D. T.; Corbin, J. D.; Granner, D. K. Regulation of phosphoenolpyruvate carboxykinase gene transcription in H4IIE hepatoma cells: Evidence for a primary role of the catalytic subunit of 3′,5′-cyclic adenosine monophosphate-dependent protein kinase. Mol. Endocrinol. 1:639-647; 1987.
58. Gottesman, M. M.; Fleischmann, R. D. The role of cAMP in regulating tumour cell growth. Cancer Surv. 5:291-308; 1986.
59. Jin, Z.; Gao, F.; Flagg, T.; Deng, X. Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J. Biol. Chem. 279:23837-23844; 2004.
60. Park, P. G.; Merryman, J.; Orloff, M.; Schuller, H. M. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: Implications for individuals with preexisting chronic lung disease. Cancer Res. 55:3504-3508; 1995.
61. Schuller, H. M.; Tithof, P. K.; Williams, M.; Plummer, 3rd, H. The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res. 59:4510-4515; 1999.
62. Jin, Z.; Gao, F.; Flagg, T.; Deng, X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J. Biol. Chem. 279:40209-40219; 2004.
63. Narita, S.; Shibata, O.; Waki, S.; Egashira, K.; Suzuki, T. Adrenaline and noradrenaline secretion of the adrenal gland in conscious dogs in response to pilocarpine and nicotine. Tohoku J. Exp. Med. 110:303-305; 1973.
64. Entschladen, F.; Drell, 4th, T. L.; Lang, K.; Joseph, J.; Zaenker, K. S. Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr. Pharm. Des. 11(3):403-411; 2005.
65. Weddle, D. L.; Tithoff, P.; Williams, M.; Schuller, H. M. Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 22:473-479; 2001.
66. Kawabe, A.; Shimada, Y.; Uchida, S.; Maeda, M.; Yamasaki, S.; Kato, M.; et al. Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: Comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression. J. Surg. Oncol. 80:79-88; 2002.
67. Shin, V. Y.; Wu, W. K.; Chu, K. M.; Koo, M. W.; Wong, H. P.; Lam, E. K.; et al. Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells. Toxicol. Sci. 96:21-29; 2007.
68. Lutgendorf, S. K.; Cole, S.; Costanzo, E.; Bradley, S.; Coffin, J.; Jabbari, S.; et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin. Cancer Res. 9:4514-4521; 2003.
69. Wu, W. K.; Wong, H. P.; Luo, S. W.; Chan, K.; Huang, F. Y.; Hui, M. K.; et al. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone from cigarette smoke stimulates colon cancer growth via beta-adrenoceptors. Cancer Res. 65:5272-5277; 2005.
70. Wong, H. P.; Yu, L.; Lam, E. K.; Tai, E. K.; Wu, W. K.; Cho, C. H. Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol. Sci. 97:279-287; 2007.
71. Kasbohm, E. A.; Guo, R.; Yowell, C. W.; Bagchi, G.; Kelly, P.; Arora, P.; et al. Androgen receptor activation by G(s) signaling in prostate cancer cells. J. Biol. Chem. 280:11583-11589; 2005.
72. Morita, K.; Arimochi, H.; Tsuruo, Y. Adrenergic activation of steroid 5alpha-reductase gene expression in rat C6 glioma cells: Involvement of cyclic amp/protein kinase A-mediated signaling pathway. J. Mol. Neurosci. 22:205-212; 2004.
73. Cox, M. E.; Deeble, P. D.; Lakhani, S.; Parsons, S. J. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res. 59:3821-3830; 1999.
74. Ramberg, H.; Eide, T.; Krobert, K. A.; Levy, F. O.; Dizeyi, N.; Bjartell, A. S.; et al. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate 68:1133-1142; 2008.
75. Spiegel, D.; Giese-Davis, J. Depression and cancer: Mechanisms and disease progression. Biol. Psychiatry 54:269-282; 2003.
76. Cohen, S.; Rabin, B. S. Psychologic stress, immunity, and cancer. J. Natl. Cancer Inst. 90:3-4; 1998.
77. Uotila, P. The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol. Immunother. 43:1-9; 1996.
78. Thaker, P. H.; Sood, A. K. Neuroendocrine influences on cancer biology. Semin. Cancer Biol. 18:164-170; 2008.
79. Thaker, P. H.; Lutgendorf, S. K.; Sood, A. K. The neuroendocrine impact of chronic stress on cancer. Cell Cycle 6:430-433; 2007.
80. Summers, R. J.; McMartin, L. R. Adrenoceptors and their second messenger systems. J. Neurochem. 60:10-23; 1993.